Alvogen Launches First Generic Equivalent of Zoladex

PINE BROOK, N.J.–(BUSINESS WIRE)–Alvogen today announced the launch of the first generic
equivalent of Zoladex^TM in Central and Eastern Europe. The
product will be marketed in two strengths (3.6mg and 10.8mg) under the
brand name Reseligo^TM and will be launched in Bulgaria,
Croatia, Baltics, Romania, Hungary, Iceland and Poland from May 2016.
Astra Zeneca‘s Zoladex^TM, delivered sales of over EUR 200
million in Europe in 2015, according to IMS.
Reseligo^TM contains the active ingredient goserelin and
belongs to the class of GnRH agonists (analogues of gonadotropin
releasing hormone) which interfere with the regulation of the sex
hormone balance. As a consequence, testosterone levels are lowered in
men and estradiol levels are lowered in women. This artificially induced
lowering of hormone levels enables the symptomatic therapy of
hormonesensitive tumors such as prostate cancer or breast cancer with
goserelin. In addition, goserelin is used to treat certain benign
gynecological disorders. Goserelin is administered in the form of a
biodegradable implant which releases the active ingredient over a period
of either one or three months.
Hacho Hatchikian, Executive Vice President at Alvogen in the CEE
region, commented: “We are delighted about the launch of Reseligo^TM.
This product represents an important milestone in the further
development of our oncology portfolio in the region. After already being
on the market in the CEE region with three biosimilar products, this is
yet another first-to-market complex product in our portfolio, which
reaffirms Alvogen’s leadership position in delivering difficult-to-make
but affordable treatments to patients. Reseligo^TM offers a
more affordable – but equally effective – treatment option for cancer
patients, offering compelling cost saving opportunities within the
Central and Eastern European region.”Zoladex^TM is a
trademark of the AstraZeneca group of companies.
About Alvogen
Alvogen is a global, privately owned pharmaceutical company focused on
developing, manufacturing and selling generic, brand, over-the-counter
brands (OTC) and biosimilar products for patients around the world.
The company has commercial operations in 35 countries with 2,300
employees and operates four manufacturing and development hubs in the
US, Romania, Korea and Taiwan. North America is Alvogen’s single largest
market and other key markets include: South Korea, West Balkan, Poland,
Romania, Bulgaria, Hungary, Taiwan, Thailand, Ukraine, Russia, Japan and
China.